Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of simvastatin plus rifaximin in decompensated cirrhosis
2016-004499-23Phase 2Completed
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis comparing Simvastatin + rifaximin with Placebo (2 arms). Primary endpoint: Change in liver and muscle enzymes. Started Jan 2017; status: completed.
02
Drugs
simvastatinrifaximin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2016-004499-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004499-23.